Search

Search Constraints

You searched for: Author/Creator McAllister, P

Search Results

2. P.015 Monthly migraine days, acute medication use-days, and migraine-specific quality of life in responders to atogepant: a post hoc analysis. (June 2022)

4. P.020 Long-term safety and tolerability of atogepant 60mg once daily for preventive treatment of migraine: a phase 3, 40-week, multicenter extension to the advance trial. (June 2022)

6. P.029 Oral Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days. (November 2021)